Stockscreener 앱 받기
45.86
3.01%
-1.05
전일 마감가:
$46.91
열려 있는:
$47.99
하루 거래량:
1.13M
Relative Volume:
1.21
시가총액:
$337.70M
수익:
-
순이익/손실:
$-121.02M
주가수익비율:
-4.0728
EPS:
-11.26
순현금흐름:
$-114.09M
1주 성능:
+6.36%
1개월 성능:
+40.61%
6개월 성능:
+90.46%
1년 성능:
-18.78%
1일 변동 폭
$45.20
$50.29
1주일 범위
$43.80
$50.40
52주 변동 폭
$7.31
$130.00
토닉스 파마슈티컬스 홀딩 Stock (TNXP) Company Profile
명칭
Tonix Pharmaceuticals Holding Corp
전화
212-980-9155
주소
26 MAIN STREET, SUITE 101, CHATHAM, NY
TNXP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
45.90 | 314.74M | 0 | -121.02M | -114.09M | -11.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.68 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.43 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
567.36 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
292.00 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
토닉스 파마슈티컬스 홀딩 Stock (TNXP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-04-18 | 개시 | Noble Capital Markets | Outperform |
| 2019-04-18 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2017-08-18 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2016-09-07 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2016-02-17 | 재확인 | Oppenheimer | Outperform |
| 2015-11-04 | 개시 | Cantor Fitzgerald | Buy |
| 2015-06-12 | 개시 | Oppenheimer | Outperform |
| 2015-02-17 | 재확인 | ROTH Capital | Buy |
| 2014-09-29 | 재확인 | ROTH Capital | Buy |
모두보기
토닉스 파마슈티컬스 홀딩 주식(TNXP)의 최신 뉴스
Tonix Pharma Launches Move Fibro Forward Campaign - TipRanks
Tonix Pharmaceuticals Announces the Launch of the “Move - GlobeNewswire
Tonix Tackles 15-Year Fibromyalgia Treatment Void with Groundbreaking Patient Support Campaign - Stock Titan
Tonix Pharmaceuticals Holding Corp. Stock Analysis and ForecastHigh-octane financial growth - jammulinksnews.com
Is Tonix Pharmaceuticals Holding Corp. a good long term investmentUnmatched profit potential - Autocar Professional
What drives Tonix Pharmaceuticals Holding Corp. stock priceFree Stock Market Mentorship - Autocar Professional
What analysts say about Tonix Pharmaceuticals Holding Corp. stockSuperior returns - Autocar Professional
Tonix targets August PDUFA date for Fibromyalgia drug candidate, advances mpox vaccine strategy - Proactive financial news
Are TNXP Shares Ready for a Comeback? - StocksToTrade
Tonix Pharma Plans Sales Force for TNX-102 SL - TipRanks
Tonix Pharmaceuticals ($TNXP) Skyrockets 284% in 2025: Earnings Catalysts.... - Investing.com India
Tonix reports TNX-801 vaccine shows promise against mpox By Investing.com - Investing.com South Africa
Tonix Pharmaceuticals Shares Climb on Encouraging TNX-801 Vaccine Results - MSN
Tonix Pharmaceuticals Announces Presentation of New Data on - GlobeNewswire
Tonix Pharma stock up after data for pain drug (TNXP:NASDAQ) - Seeking Alpha
Tonix Pharmaceuticals stock rises on promising TNX-801 vaccine data By Investing.com - Investing.com India
Tonix Pharmaceuticals stock rises on promising TNX-801 vaccine data - Investing.com Australia
Tonix reports TNX-801 vaccine shows promise against mpox - Investing.com
Tonix Pharma Unveils Promising TNX-801 Vaccine Findings - TipRanks
Revolutionary Mpox and Smallpox Vaccine Achieves 100,000-Fold Safety Improvement with Single-Dose Protection - Stock Titan
Tonix Pharmaceuticals shares rise 1.75% premarket after publishing positive Phase 3 trial results for TNX-102 SL. - AInvest
Tonix Pharmaceuticals Announces On-line Publication of - GlobeNewswire
Tonix Pharmaceuticals' TNX-102 SL: A Breakthrough in Fibromyalgia Treatment and Its Implications for Investors - AInvest
Tonix’s fibromyalgia drug shows positive results in phase 3 trial By Investing.com - Investing.com South Africa
Tonix’s fibromyalgia drug shows positive results in phase 3 trial - Investing.com Australia
Tonix Pharma Publishes Phase 3 Trial Results - TipRanks
Tonix Pharmaceuticals Announces Publication of Positive Phase 3 RESILIENT Trial Data for TNX-102 SL in Fibromyalgia Management - Nasdaq
Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine - Yahoo Finance
Breakthrough Fibromyalgia Treatment Shows Superior Pain Relief in Phase 3 Trial, FDA Decision Looms - Stock Titan
Tonix Pharmaceuticals Announces Efficacy and Safety of Single-Dose TNX-801 Vaccine Against Monkeypox - Quiver Quantitative
Tonix Pharmaceuticals Announces Oral Presentation on Mpox - GlobeNewswire
Breakthrough: New Single-Dose Vaccine Demonstrates 100% Protection Against Deadly Mpox Challenge - Stock Titan
Tonix Pharmaceuticals Announces Peer-Reviewed Publication - GlobeNewswire
Tonix Pharma Publishes Study on TNX-1700 Efficacy - TipRanks
Tonix Pharmaceuticals Holding Corp.(NasdaqCM: TNXP) added to Russell 3000E Index - MarketScreener
Tonix Pharmaceuticals Joins Elite Russell Indexes Ahead of Major FDA Decision - Stock Titan
Tonix Pharmaceuticals Holding Corp.(NasdaqCM: TNXP) added to Russell 2500 Index - MarketScreener
How To Trade (TNXP) - news.stocktradersdaily.com
Tonix Pharmaceuticals Reports Promising Phase 3 Results for Fibromyalgia Treatment at EULAR 2025 - citybuzz -
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL - GuruFocus
Tonix Pharmaceuticals: Big Risk, Bigger RewardInitiating With A Buy (NASDAQ:TNXP) - Seeking Alpha
Tonix Pharma Presents Data at Rheumatology Congress - TipRanks
Tonix Pharmaceuticals (TNXP) Highlights Fibromyalgia Treatment a - GuruFocus
Tonix Pharmaceuticals (TNXP) Highlights Fibromyalgia Treatment at EULAR 2025 | TNXP Stock News - GuruFocus
Tonix Pharmaceuticals Presented Data and Analyses of - GlobeNewswire
First New Fibromyalgia Treatment in 15 Years Shows Breakthrough Results, FDA Decision Approaches - Stock Titan
Tonix Pharmaceuticals (TNXP) Welcomes New Board Member | TNXP St - GuruFocus
Tonix Pharmaceuticals Announces Appointment of Commercial - GlobeNewswire
Tonix Pharmaceuticals Strengthens Board with Appointment of Jim Hunter - citybuzz -
Tonix Pharmaceuticals Announces Appointment of Commercial Indust - GuruFocus
Tonix Pharmaceuticals Appoints James “Jim” Hunter To Board - citybiz
토닉스 파마슈티컬스 홀딩 (TNXP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.03%
0.17%
자본화:
|
볼륨(24시간):